Immune Checkpoint Inhibitors PD-1 PD-L1 CTLA-4 Cancer Immunotherapy

# Immune Checkpoint Inhibitors PD-1 PD-L1 CTLA-4 Cancer Immunotherapy

## Clinical Pearl
If you remember ONE thing, it's that PD-1/PD-L1 and CTLA-4 are the 'brakes' of the immune system, and checkpoint inhibitors (like pembrolizumab for PD-1 or ipilimumab for CTLA-4) 'take the brakes off' T-cells to attack cancer. CTLA-4 acts early in the lymph node by outcompeting CD28 for B7 (CD80/86), while PD-1 acts late in the peripheral tumor microenvironment. High PD-L1 expression on a tumor biopsy often predicts a better clinical response to anti-PD-1/PD-L1 monoclonal antibody therapies.

## Process Steps
undefined. In the lymph node pit stop, the Cytotoxic T-Cell (Turbo Car) attempts to accelerate using the CD28 turbo intake, which receives high-octane fuel from the B7 nozzle.
undefined. The CTLA-4 restrictor plate deploys, outcompeting the CD28 intake for the B7 fuel nozzle, dampening the T-Cell car's initial acceleration.
undefined. The T-Cell car enters the peripheral track and approaches the Tumor Cell (Rogue Car), preparing to initiate a cytotoxic attack.
undefined. The Tumor Cell deploys the PD-L1 grappling hook, which latches onto the T-Cell's PD-1 emergency brake, halting the attack and allowing the tumor to evade.
undefined. Immune checkpoint inhibitor drugs act as mechanic's bolt cutters, severing the PD-L1/PD-1 and CTLA-4 connections, restoring the T-Cell car's speed to destroy the Tumor Cell.

## Phonetic & Etymology Clues
Cytotoxic T-Cell: Cyto (Scythe) + toxic (toxic green exhaust) + T (Turbo) = Scythe-wielding, toxic-exhaust Turbo car,Tumor Cell: Tu (Two) + mor (motors) = Two-motor rogue vehicle,PD-1: P (Police) + D (Department) + 1 (Badge 1) = Police Department Badge 1 emergency brake,PD-L1: P (Police) + D (Department) + L (Lock) + 1 = Police Department Lock 1 grappling hook,CTLA-4: C (City) + T (Traffic) + LA (Los Angeles) + 4 (4-way) = City Traffic LA 4-way restrictor plate,CD28: C (Compact) + D (Disc) + 28 = Compact Disc track 28 turbo intake,B7 Ligand: B (Bee) + 7 (Seven) = 7-Bee high-octane fuel nozzle

## Entity Summary
- **Cytotoxic T-Cell**: Effector immune cell responsible for recognizing and destroying malignant or infected cells. → Tumor Cell, PD-1, CTLA-4
- **Tumor Cell**: Malignant cell that attempts to evade immune destruction by expressing inhibitory ligands on its surface. → Cytotoxic T-Cell, PD-L1
- **PD-1**: Inhibitory immune checkpoint receptor expressed on activated T-cells to prevent overactivity and autoimmunity in peripheral tissues. → Cytotoxic T-Cell, PD-L1
- **PD-L1**: Transmembrane ligand expressed on tumor cells that binds to PD-1 to suppress T-cell activation and induce immune tolerance. → Tumor Cell, PD-1
- **CTLA-4**: Inhibitory receptor on T-cells that outcompetes CD28 for B7 binding, dampening early T-cell activation in the lymph node. → Cytotoxic T-Cell, B7 Ligand, CD28
- **CD28**: Co-stimulatory receptor on T-cells that provides the necessary secondary signal for full T-cell activation and survival. → Cytotoxic T-Cell, B7 Ligand, CTLA-4
- **B7 Ligand**: Co-stimulatory molecule (CD80/86) on antigen-presenting cells that binds either CD28 (activating) or CTLA-4 (inhibitory). → CD28, CTLA-4

If you remember ONE thing, it's that PD-1/PD-L1 and CTLA-4 are the 'brakes' of the immune system, and checkpoint inhibitors (like pembrolizumab for PD-1 or ipilimumab for CTLA-4) 'take the brakes off' T-cells to attack cancer. CTLA-4 acts early in the lymph node by outcompeting CD28 for B7 (CD80/86), while PD-1 acts late in the peripheral tumor microenvironment. High PD-L1 expression on a tumor biopsy often predicts a better clinical response to anti-PD-1/PD-L1 monoclonal antibody therapies.